Merck & Company (MRK) Stock Forecast & Price Target
MRK Analyst Ratings
Moderate Buy
15Buy6Hold0Sell
Based on 21 analysts giving stock ratings to Merck & Company in the past 3 months
MRK Stock 12 Month Forecast
Average Price Target
MXN 3,052.62â–²(8.48% Upside)Based on 21 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is MXN 3,052.62 with a high forecast of MXN 3,398.79 and a low forecast of MXN 1,982.63. The average price target represents a 8.48% change from the last price of MXN 2,814.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 3.4K
AverageMXN 3.05K
LowMXN 1.98K
Highest Price TargetHighestMXN 3,398.79Average Price TargetMXN 3,052.62Lowest Price TargetLowestMXN 1,982.63
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Louise Chen | Scotiabank | MXN 3,398.79 | buy | 20.78%Upside | Assigned | 10/30/26 | ||
| Jason Gerberry | Bank of America Securities | MXN 3,077.79→MXN 3,115.56 | buy | 10.72%Upside | Reiterated | 10/30/26 | ||
| Evan Seigerman | BMO Capital | MXN 3,209.97 | buy | 14.07%Upside | Reiterated | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | MXN 3,342.15→MXN 3,285.50 | buy | 16.76%Upside | Assigned | 10/30/26 | ||
| Chris Schott | J.P. Morgan | MXN 3,115.56→MXN 3,304.38 | buy | 17.43%Upside | Assigned | 10/30/26 | ||
| Vamil Divan | Guggenheim | MXN 3,209.97→MXN 3,228.85 | buy | 14.74%Upside | Reiterated | 10/29/26 | ||
| Emily Field | Barclays | MXN 3,398.79 | buy | 20.78%Upside | Reiterated | 10/28/26 | ||
| Geoff Meacham | Citi | MXN 2,737.92 | hold | -2.70%Downside | Reiterated | 10/27/26 | ||
| Trung Huynh | RBC Capital | MXN 2,737.92 | hold | -2.70%Downside | Reiterated | 10/27/26 | ||
| Mohit Bansal | Wells Fargo | MXN 3,115.56 | buy | 10.72%Upside | Reiterated | 10/26/26 | ||
| Carter Gould | Cantor Fitzgerald | MXN 2,737.92 | hold | -2.70%Downside | Reiterated | 10/26/26 | ||
| Courtney Breen | Bernstein | MXN 1,982.63 | hold | -29.54%Downside | Reiterated | 10/25/26 | ||
| Michael Yee | UBS | MXN 3,304.38 | buy | 17.43%Upside | Reiterated | 10/24/26 | ||
| Asad Haider | Goldman Sachs | MXN 2,926.74 | buy | 4.01%Upside | Reiterated | 10/22/26 | ||
| Daina Graybosch | Leerink Partners | MXN 3,040.03 | buy | 8.03%Upside | Reiterated | 10/12/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Louise Chen | 10/30/26 | MXN 3,398.79 | buy | 20.78%Upside | Assigned | Scotiabank | ||
| Jason Gerberry | 10/30/26 | MXN 3,077.79→MXN 3,115.56 | buy | 10.72%Upside | Reiterated | Bank of America Securities | ||
| Evan Seigerman | 10/30/26 | MXN 3,209.97 | buy | 14.07%Upside | Reiterated | BMO Capital | ||
| Terence Flynn | 10/30/26 | MXN 3,342.15→MXN 3,285.50 | buy | 16.76%Upside | Assigned | Morgan Stanley | ||
| Chris Schott | 10/30/26 | MXN 3,115.56→MXN 3,304.38 | buy | 17.43%Upside | Assigned | J.P. Morgan | ||
| Vamil Divan | 10/29/26 | MXN 3,209.97→MXN 3,228.85 | buy | 14.74%Upside | Reiterated | Guggenheim | ||
| Emily Field | 10/28/26 | MXN 3,398.79 | buy | 20.78%Upside | Reiterated | Barclays | ||
| Geoff Meacham | 10/27/26 | MXN 2,737.92 | hold | -2.70%Downside | Reiterated | Citi | ||
| Trung Huynh | 10/27/26 | MXN 2,737.92 | hold | -2.70%Downside | Reiterated | RBC Capital | ||
| Mohit Bansal | 10/26/26 | MXN 3,115.56 | buy | 10.72%Upside | Reiterated | Wells Fargo | ||
| Carter Gould | 10/26/26 | MXN 2,737.92 | hold | -2.70%Downside | Reiterated | Cantor Fitzgerald | ||
| Courtney Breen | 10/25/26 | MXN 1,982.63 | hold | -29.54%Downside | Reiterated | Bernstein | ||
| Michael Yee | 10/24/26 | MXN 3,304.38 | buy | 17.43%Upside | Reiterated | UBS | ||
| Asad Haider | 10/22/26 | MXN 2,926.74 | buy | 4.01%Upside | Reiterated | Goldman Sachs | ||
| Daina Graybosch | 10/12/26 | MXN 3,040.03 | buy | 8.03%Upside | Reiterated | Leerink Partners |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Merck & Company
3 Months
Success Rate14/15 ratings generated profit
93%
Average Return
+10.04%
Copying Asad Haider's trades and holding each position for 3 Months would result in 93.33% of your transactions generating a profit, with an average return of +10.04% per trade.
1 Year
Success Rate15/15 ratings generated profit
100%
Average Return
+34.91%
Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.91% per trade.
2 Years
Success Rate15/15 ratings generated profit
100%
Average Return
+41.54%
Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.54% per trade.
MRK Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 0 |
| Buy | 43 | 44 | 52 | 54 | 64 |
| Hold | 18 | 16 | 16 | 17 | 23 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 62 | 60 | 68 | 71 | 87 |
In the current month, MRK has received 64 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. MRK average Analyst price target in the past 3 months is 3,052.62.
MRK Financial Forecast
HighMXN 36.90
ConsensusMXN 33.65
LowMXN 32.12
MRK Earnings Forecast
Next quarter’s earnings estimate for MRK is MXN 33.65 with a range of MXN 32.12 to MXN 36.90. The previous quarter’s EPS was MXN 46.78. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 315B
ConsensusMXN 308B
LowMXN 299B
MRK Sales Forecast
Next quarter’s sales forecast for MRK is MXN 307.67B with a range of MXN 299.03B to MXN 314.85B. The previous quarter’s sales results were MXN 339.75B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
MRK Stock Forecast FAQ
What is MX:MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is Mex$3,052.62.
What is MX:MRK’s upside potential, based on the analysts’ average price target?
Merck & Company has 8.48% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Merck & Company a Buy, Sell or Hold?
Merck & Company has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.
What is Merck & Company’s share price target?
The average share price target for Merck & Company is Mex$3,052.62. This is based on 21 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$3,398.79, and the lowest forecast is Mex$1,982.63. The average share price target represents a 8.48% increase from the current price of Mex$2,814.
What do analysts say about Merck & Company?
Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Street analysts.
How can I buy shares of Merck & Company?
To buy shares of MX:MRK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.